View DividendTASCOM マネジメントマネジメント 基準チェック /04現在、CEO に関する十分な情報がありません。主要情報 最高経営責任者n/a報酬総額CEO給与比率n/aCEO在任期間no dataCEOの所有権n/a経営陣の平均在職期間データなし取締役会の平均在任期間データなし経営陣の近況YIDOBIO Inc., Annual General Meeting, Mar 23, 2021Feb 20すべての更新を表示Recent updatesNew major risk - Market cap size Oct 25TASCOM Co.,Ltd. announced that it has received KRW 1.566576 billion in funding from SV Investment Corporation and other investorsAug 13YIDOBIO Inc. (XKON:A336040) entered into a merger agreement to acquire TASCOM CO.,LTD from Lee Seong-dong and other shareholders for KRW 16.6 billion.Jun 25YIDOBIO Inc., Annual General Meeting, Mar 23, 2021Feb 20YIDOBIO Inc. announced that it has received KRW 2.759978 billion in funding from Global Trading co.ltd, Korea Medix, Inc.Feb 17YIDOBIO Inc. announced that it expects to receive KRW 2.759978 billion in funding from Global Trading co.ltd, Korea Medix, Inc. and other investorsJan 29New 90-day high: ₩25,800 Dec 15New 90-day high: ₩20,750 Nov 13New 90-day high: ₩20,650 Sep 17New 90-day high - ₩20,200 Aug 31New 90-day low - ₩16,500 Jul 27CEO（最高経営責任者TASCOM CEOがいない、あるいは彼らに関するデータがない。View Ownership
TASCOM Co.,Ltd. announced that it has received KRW 1.566576 billion in funding from SV Investment Corporation and other investorsAug 13
YIDOBIO Inc. (XKON:A336040) entered into a merger agreement to acquire TASCOM CO.,LTD from Lee Seong-dong and other shareholders for KRW 16.6 billion.Jun 25
YIDOBIO Inc. announced that it has received KRW 2.759978 billion in funding from Global Trading co.ltd, Korea Medix, Inc.Feb 17
YIDOBIO Inc. announced that it expects to receive KRW 2.759978 billion in funding from Global Trading co.ltd, Korea Medix, Inc. and other investorsJan 29